PharmaBlock Sciences, a Nanjing CRO/CMO, has been approved by China's National Equities Exchange and Quotations (NEEQ) to list on the New Third Board, the over-the-counter stock exchange in China. The company said it plans to file by the end of the year for a listing on Shenzhen's Growth Equity Market. Founded in 2006, PharmaBlock provides development services for chemical and biological drug makers.
